Apremax
Oral immunosuppressant, phosphodiesterase 4 (PDEA 4) indicated to treat moderate to severe plaque psoriasis and active psoriatic arthritis with inadequate response to other disease modifying drugs.
Therapeutic Area
Rheumatology + Dermatology + Psoriasis
Active Ingredient
Apremilast
Line
Dermatology + Oncology + Rheumatology
Pharmaceutical Forms
Starter kit:
10 mg tablets x 4
20 mg tablets x 4
30 mg tablets x 19
30 mg tablets x 30
Apremax 30 mg: 56 and 168 coated tablets
